AVEO Oncology, an LG Chem company, and HiberCell enter into an exclusive development and option agreement for first-in-human compound November 10, 2025 Categories: Health Care Tags: HiberCell
HiberCell receives FDA Fast Track designation for HC-7366 for the treatment of relapsed or refractory acute myeloid leukemia (AML) October 28, 2024 Categories: Health Care Tags: HiberCell
HiberCell announces first patient dosed in clinical collaboration with Merck, evaluating HC-7366 in combination with WELIREG® in patients with advanced ccRCC May 6, 2024 Categories: Health Care Tags: HiberCell
HiberCell Inc and Merck join forces to revolutionize treatment of clear cell renal cell carcinoma December 10, 2023 Categories: Health Care Tags: HiberCell
HiberCell announces successful completion and interim results of phase 1 study of novel PERK inhibitor, HC-5404 November 29, 2023 Categories: Health Care Tags: HiberCell
HiberCell and Strasbourg Institute for Precision Medicine publish machine learning data and approach on causal biology of severe COVID-19 October 28, 2021 Categories: Health Care Tags: HiberCell
HiberCell Receives fast track designation from FDA for first-in-human studies of PERK Inhibitor HC-5404-FU September 10, 2021 Categories: Health Care Tags: HiberCell
HiberCell closes $67.4 million Series B financing May 19, 2021 Categories: Health Care Tags: HiberCell
